Skip to Main Content

WASHINGTON — In the past year alone, President Trump has bellyached about drug makers charging “rip-off” prices, numerous Democrats have accused the pharmaceutical industry of pure greed, and polls have shown that voters believe lowering the cost of prescription medicines should be among government’s top priorities.

But if Republicans prevail in just two nailbiter races on Tuesday, the Senate’s ranks would suddenly include two former drug industry lobbyists and even a pharma CEO.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Fails to mention all of advantages Mylan received by having Manchin ignore issues and sway at the time a Democrat-majority Senate to do the same. Maybe having people with insider knowledge of the industry is a good thing, nothing else has worked.

  • Hey another biased article from STAT! Fails to mention all of advantages Mylan received by having Manchin ignore issues and sway at the time a Democrat-majority Senate to do the same. Maybe having people with insider knowledge of the industry is a good thing, nothing else has worked.

Comments are closed.